BARD1 and ovarian carcinoma: We were unable to identify mutations in EMSY, BRIP, BARD1, and FOXM1 CNV in high-grade ovarian carcinoma as well as PTEN loss in clear cell carcinoma, LRPB1 loss and SOX17 amplification in uterine serous carcinoma (Table 2).